Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariano Barbacid

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Cell|May 22, 2007
Returning homeMariano Barbacid
Cancer Cell|May 26, 2012
Opening a new GATAway for treating KRAS-driven lung tumorsMariano Barbacid
Molecular Oncology|December 24, 2021
Targeting KRAS mutant lung cancer: light at the end of the tunnelMatthias Drosten, Mariano Barbacid
Trends in Biochemical Sciences|October 21, 2005
Mammalian cyclin-dependent kinasesMarcos Malumbres, Mariano Barbacid
Molecular Oncology|November 16, 2022
KRAS inhibitors: going noncovalentMatthias Drosten, Mariano Barbacid
Nature Reviews. Cancer|June 5, 2003
RAS oncogenes: the first 30 yearsMarcos Malumbres, Mariano Barbacid
Cancer Cell|April 15, 2020
Targeting the MAPK Pathway in KRAS-Driven TumorsMatthias Drosten, Mariano Barbacid
Current Opinion in Genetics & Development|January 9, 2007
Cell cycle kinases in cancerMarcos Malumbres, Mariano Barbacid
Cancer Cell|January 18, 2006
Is Cyclin D1-CDK4 kinase a bona fide cancer target?Marcos Malumbres, Mariano Barbacid
Nature Reviews. Cancer|February 25, 2009
Cell cycle, CDKs and cancer: a changing paradigmMarcos Malumbres, Mariano Barbacid
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Cell|May 22, 2007
Returning homeMariano Barbacid
Cancer Cell|May 26, 2012
Opening a new GATAway for treating KRAS-driven lung tumorsMariano Barbacid
Molecular Oncology|December 24, 2021
Targeting KRAS mutant lung cancer: light at the end of the tunnelMatthias Drosten, Mariano Barbacid
Trends in Biochemical Sciences|October 21, 2005
Mammalian cyclin-dependent kinasesMarcos Malumbres, Mariano Barbacid
Molecular Oncology|November 16, 2022
KRAS inhibitors: going noncovalentMatthias Drosten, Mariano Barbacid
Nature Reviews. Cancer|June 5, 2003
RAS oncogenes: the first 30 yearsMarcos Malumbres, Mariano Barbacid
Cancer Cell|April 15, 2020
Targeting the MAPK Pathway in KRAS-Driven TumorsMatthias Drosten, Mariano Barbacid
Current Opinion in Genetics & Development|January 9, 2007
Cell cycle kinases in cancerMarcos Malumbres, Mariano Barbacid
Cancer Cell|January 18, 2006
Is Cyclin D1-CDK4 kinase a bona fide cancer target?Marcos Malumbres, Mariano Barbacid
Nature Reviews. Cancer|February 25, 2009
Cell cycle, CDKs and cancer: a changing paradigmMarcos Malumbres, Mariano Barbacid
Pageof 13